Company / R&D Expense
Artivion R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$31.0M
FY2025
5-year range
$23.0M / $31.0M
FY2021-FY2025
Trend
+8.9%
vs FY2024
Sector context
#94 of 110
Health Care
What the data says
Artivion's r&d expense of $31M is lower than 85% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $9M in FY2016 to $31M in FY2025.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +6.1%.
Improved from $29M to $31M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 110This company $31.0M Sector average $298.2M
▼
-89.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2025, r&d expense increased 8.9% year-over-year.
- Ranks #94 out of 110 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.21 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.0M | +8.9% |
| FY2024 | $28.5M | -0.9% |
| FY2023 | $28.7M | +18.6% |
| FY2022 | $24.2M | +5.4% |
| FY2021 | $23.0M | -0.6% |
| FY2020 | $23.1M | +18.7% |
| FY2019 | $19.5M | +44.7% |
| FY2018 | $13.4M | +28.8% |
| FY2017 | $10.4M | +20.0% |
| FY2016 | $8.7M | +2.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026